|
Author(s)
|
Primary/Relapse
|
CAM5.2 (CK8)
|
CK18
|
AE1/AE3
|
EMA
|
Vimentin
|
Desmin
|
α-SMA
|
S-100
|
CD21
|
CD68
|
p53
|
|---|
|
Gould et al. [8]
| |
+
|
+
|
+
|
+
|
+
|
–
|
+
|
–
|
ND
|
ND
|
ND
|
|
Gould et al. [8]
| |
+
|
+
|
+
|
+
|
+
|
+
|
+
|
–
|
ND
|
ND
|
ND
|
|
Gould et al. [8]
| |
+
|
+
|
+
|
–
|
+
|
+
|
+
|
–
|
ND
|
ND
|
ND
|
|
Chan et al. [9]
| |
+
|
+
|
+
|
+/−
|
+
|
–
|
–
|
–
|
–
|
–
|
ND
|
|
Chan et al. [9]
| |
+
|
+
|
–
|
–
|
+
|
+
|
+
|
–
|
–
|
–
|
ND
|
|
Chan et al. [9]
| |
+
|
+
|
+
|
+/−
|
+
|
–
|
–
|
–
|
–
|
–
|
ND
|
|
Schuerfeld et al. [10]
| |
+
|
+
|
+
|
–
|
+
|
+
|
ND
|
+
|
–
|
+
|
ND
|
|
Lucioni et al. [11]
|
*primary
|
–
|
ND
|
–
|
–
|
+
|
–
|
+
|
–
|
–
|
+
|
20%
|
|
relapse
|
+
|
ND
|
+/−
|
–
|
+
|
–
|
–
|
–
|
–
|
–
|
> 60%
|
|
Karim et al. [12]
| |
ND
|
ND
|
+
|
ND
|
ND
|
+
|
+
|
–
|
–
|
ND
|
ND
|
|
Goto et al. [13]
| |
+
|
ND
|
+
|
+/−
|
ND
|
–
|
–
|
+/−
|
+/−
|
–
|
ND
|
|
Bösmüller et al. [14]
| |
+
|
ND
|
+
|
–
|
+
|
–
|
–
|
–
|
–
|
+
|
+/−
|
|
Current case
|
primary
|
+
|
+
|
+
|
+
|
+
|
–
|
–
|
–
|
–
|
–
|
95%
|
|
relapse
|
+
|
+
|
+
|
+
|
+
|
–
|
–
|
–
|
–
|
–
|
80%
|
- - negative, +/− often/partially positive, + positive, * primary tumor was diagnosed as fibroblastic reticulum cell tumor; ND Not done
